Background. Several investigators have sought risk factors for mortality in acute kidney injury (AKI). However, no epidemiological studies have investigated the impact of red blood cell distribution width (RDW) on prognosis for critically ill patients with AKI. The aim of this study was to investigate the association of RDW with mortality in these patients. Methods. We analyzed data from the MIMIC-III. RDW was measured upon ICU admission. The association between RDW and mortality of AKI was determined using a multivariate logistic regression and was expressed as the adjusted odds ratio with associated 95% confidence interval (CI). We also conducted subgroup analyses to determine the consistency of this association. Results. A total of 14,078 critically ill patients with AKI were eligible for this analysis. In multivariate analysis, adjusted for age and gender and compared with the reference group (RDW 11.1-13.4%) related to hospital mortality, the adjusted ORs (95% CIs) for RDW levels 13.5-14.3%, 14.4-15.6%, and 15.7-21.2% were 1.22 (1.05, 1.43), 1.56 (1.35, 1.81), and 2.66 (2.31, 3.06), respectively. After adjusting for confounding factors, with high RDW linked to an increase in mortality .4%: OR, 1.57; 95% CI, 1.22 to 2.01; P trend <0.0001). A similar trend was observed for 30-day mortality. Conclusions. RDW appeared to be an independent prognostic marker in critically ill patients with AKI and higher RDW was associated with increased risk of mortality in these patients.
Introduction
Acute kidney injury (AKI) is a common and serious syndrome. It is diagnosed with urine output and serum creatinine criteria and is associated with high morbidity and mortality, especially in critical illness [1, 2] . In addition, survivors often fail to restore kidney function and require long-term dialysis [3, 4] , which brings a huge economic burden [5] . Considering the high incidence of AKI and the poor prognosis in critical illness, several investigators have sought risk factors of mortality in AKI [6, 7] .
Red blood cell distribution width (RDW) reflects the size variation of circulating red blood cells and is calculated in automated complete blood counts [8] . Previously, the clinical use of RDW was limited to the differential diagnosis of anemia. An increased RDW was considered significantly associated with risk of adverse outcomes in patients with cardiovascular diseases [9, 10] , multiple myeloma [11] , systemic sclerosis [12] , and ischemic stroke [13] . A study demonstrated that RDW could be an additive predictor for mortality in AKI patients undergoing continuous renal replacement therapy (CRRT) [14] . Moreover, a recent study demonstrated that increased RDW was associated with increased risk of AKI and mortality in critically ill patients in the coronary care unit (CCU) [15] . Despite these observations, no epidemiological studies have investigated the impact of RDW on prognosis of critically ill patients with AKI. The aim of this study was to evaluate the association of RDW with mortality in these patients. 
Methods

The Database. Multiparameter Intelligent Monitoring in
Population Selection Criteria.
The database included a total of 58,976 ICU admissions. Patients with AKI who were over the age of 18 years and had been hospitalized in the ICU at first admission for more than two days were included. Improving Global Outcomes (KDIGO) determined the classification of AKI [17] . Patients were excluded if they met the following criteria: (1) no RDW measured during ICU stay; (2) hematologic disease such as leukemia and myelodysplastic syndrome; and (3) missing > 5% individual data.
Data Extraction.
Data extraction was performed by using Structured Query Language (SQL) with PostgreSQL (version 9.6). The following data were extracted: age, gender, ethnicity, BMI, SBP, DBP, respiratory rate, temperature, comorbidities, laboratory parameters, and scoring systems. The following comorbidities were extracted: congestive heart failure (CHF), coronary artery disease (CAD), atrial fibrillation (AF), chronic kidney disease (CKD), chronic liver disease, chronic obstructive pulmonary disease (COPD), stroke, malignancy, respiratory disease (non-COPD), and acute respiratory distress syndrome (ARDS). We extracted the following laboratory parameters: white blood cell (WBC), blood urea nitrogen (BUN), chloride, bilirubin, hematocrit, and hemoglobin. We also calculated sequential organ failure assessment (SOFA) [18] and acute physiology score III (APS III) [19] . Hospital mortality and 30-day all-cause mortality were the clinical outcomes. The baseline characteristic data were extracted within the first 24 h after patient ICU admission and were analyzed in three equal groups.
Statistical Analysis.
Baseline characteristics of all patients were stratified by RDW tertiles. Continuous variables were presented as mean ± standard deviation (SD) or medians and compared using the analysis of variance or the KruskalWallis test. Categorical data were summarized as number or percentage.
The associations between RDW and hospital mortality and 30-day all-cause mortality of AKI were determined using a multivariate logistic regression and were expressed as the adjusted odds ratio with associated 95% confidence interval (CI). We used two multivariate models to determine whether there was a significant association of RDW with mortality. We selected these confounders based on their associations with the hospital mortality of RDW or a change in effect estimate of more than 10%. In model I, covariates were adjusted for age and gender. In model II, we adjusted for age, gender, albumin, hemoglobin, liver disease, renal disease, malignancy, bilirubin, WBC, BUN, APS III, SOFA, systemic inflammatory response syndrome (SIRS), renal replacement therapy (RRT), temperature, and Elixhauser [20] . We performed stratification analyses to determine whether the effect of RDW differed across various subgroups classified by age, gender, CHF, AKI stage, AF, COPD, CAD, stroke, respiratory failure, pneumonia, ARDS, liver, vasoactive drug administration RRT, and SIRS. We generated Receiver Operating Characteristic (ROC) curves to measure the sensitivity and specificity of RDW and existing scoring systems (SOFA score or APS III score) and calculated the area under the curve (AUC) to ascertain the quality of RDW as a predictor of mortality.
A two-tailed value <0.05 was considered to be statistically significant. EmpowerStats version 2.17.8 (http://www .empowerstats.com/cn/) and R software version 3.42 were used for all statistical analysis.
Results
Subject Characteristics.
A total of 14,078 critically ill patients with AKI were eligible for this analysis. According to the RDW, there were three equal groups: 4672 patients were in the low-RDW group (11.1-13.7%), 4664 patients were in the mid-RDW group (13.8-15.1%), and 4742 patients were in the high-RDW group (15.2-21.2%). As shown in Table 1 , 8086 (57.4%) were men and 9964 (70.8%) were white. Patients in the higher RDW (15.2-21.2%) tended to be elderly, female, and white and were more likely to have a history of CHF, AF, CKD, chronic liver disease, malignancy, respiratory disease (non-COPD), and ARDS. Moreover, these patients had higher BUN and bilirubin and lower hematocrit and hemoglobin. They also had higher SOFA and APS III scores and were more likely to use RRT than were those with low-RDW group (11.1-13.7%).
RDW Levels and Mortality.
Higher RDW was associated with increased risk of hospital mortality and 30-day all-cause mortality in critically ill patients with AKI (Table 2 ). In multivariate analysis, adjusted for age and gender and compared with reference group (RDW 11.1-13.4%), the adjusted ORs (95% CIs) for RDW levels 13.5-14.3%, 14.4-15.6%, and 15.7-21.2% were 1.22 (1.05, 1.43), 1.56 (1.35, 1.81), and 2.66 (2.31, 3.06), respectively. After adjusting for age, gender, albumin, hemoglobin, liver disease, renal disease, malignancy, bilirubin, WBC, BUN, APS III, SOFA, SIRS, RRT, temperature, and Elixhauser, a similar trend was observed: high RDW was associated with an increase in mortality (RDW 15.7-21.2% versus 11.1-13.4%: OR, 1.57; 95% CI, 1.22 to 2.01; P trend <0.0001). Meanwhile, a similar trend was observed for 30-day all-cause mortality ( Table 2) .
Subgroup Analyses.
We conducted subgroup analyses to determine the consistency of association between RDW and risk of hospital mortality in critically ill patients with AKI (Table 3) . Patients who were female showed an increased risk of hospital mortality with higher RDW (OR 1.08, 95% CI 1.02 to 1.14) . Similarly, patients with respiratory failure (OR, 1.09; 95% CI, 1.04 to 1.14), pneumonia (OR, 1.08; 95% CI, 1.02 to 1.14), and treatment with vasoactive agents (OR, 1.09; 95% CI, 1.04 to 1.14) had a significantly higher risk of hospital mortality with higher RDW.
Prediction of Mortality.
ROC curves generated using the indicated variables (SOFA scores, RDW plus SOFA scores and APS III scores, and RDW plus APS III scores) were plotted in Figure 1 . The AUC for SOFA scores was 0.648, compared to 0.669 for RDW plus SOFA scores (P < 0.0001). Furthermore, the AUCs for the relationships between APS III scores and RDW plus APS III scores were 0.702 and 0.708 (P = 0.0028).
Discussion
We observed that higher RDW was associated with increased risk of hospital mortality and 30-day all-cause mortality in critically ill patients with AKI. Furthermore, after adjusting for age, gender, albumin, hemoglobin, liver disease, renal disease, malignancy, bilirubin, WBC, BUN, APS III, SOFA, SIRS, RRT, temperature, and Elixhauser, the high RDW was associated with an increase in mortality. Several studies demonstrated that RDW was independently associated with numerous adverse outcomes [10, 21, 22] , and the results of our study also indicated that RDW was an independent predictor of mortality in critically ill patients with AKI. AKI is a common, dangerous complication with a high mortality rate [23] . It is associated with local and systemic inflammation [24] . These inflammatory mediators are white blood cells, macrophages, components of endothelial cells, mast cells, fibroblasts, neutrophil, lymphocyte, and platelets [16, 25] . Diverse biomarkers have been determined to predict the prognosis of AKI in several studies [26, 27] . Similarly, our study showed that RDW was one of these biomarkers. RDW is an easily available biomarker and has been regarded as a useful predictive index for numerous diseases and organ dysfunctions [28] [29] [30] . Researchers in many observational studies [31, 32] have described an association between increased RDW and changes in inflammatory biomarkers. Therefore, the systemic inflammatory response probably helps to explain the potential link between RDW and the mortality in critically ill patients with AKI; however, the precise mechanisms for these relationships remain unknown.
In some studies, several possible explanations for these mechanisms have been proposed. Iron metabolism and bone marrow function were inhibited by inflammation [33] . Maturation and proliferation of erythrocyte were also inhibited by proinflammatory cytokines [34] . Furthermore, extent of inflammation played a negative impact on patient survival [35] . Moreover, the occurrence and progression of AKI were closely related to the inflammatory response. These revealed a close connection between RDW and AKI. In addition, oxidative stress resulted in a change in the size of red blood cells, reflected in an increase in RDW. Several studies demonstrated that oxidative stress, RDW, and allcause mortality were closely related to each other [36, 37] . In subgroup analysis, we found the prognostic impact of RDW seemed to be weak in patients with baseline cardiac and cerebrovascular disease. On the other hand, the impact of RDW was significant in patients with respiratory failure, not in those with ARDS. In our study, subgroup analysis was based on the analysis of patients with AKI. If RDW independently predicted the prognosis of these diseases, the confounding factors that needed to be adjusted were different. Furthermore, the prognostic impact of RDW was not significant in patients requiring RRT. This was inconsistent with previous research [14] . To our knowledge, different sample sizes, research centers, and patient characteristics could lead to inconsistent results. Therefore, further studies, especially large prospective studies, are needed to confirm the relationship between RDW and adverse clinical outcomes.
The major strength of our study was that it was, to the best of our knowledge, the first study to comprehensively examine the relationship between RDW and mortality of AKI in critically ill patients. The RDW appears to be an independent prognostic marker in critically ill patients with AKI. Furthermore, the number of patients enrolled was very large.
This study also has some limitations. First, it had a singlecenter retrospective design, possibly affected by selection bias. Second, we measured RDW in patients only upon admission to the ICU and did not assess changes during the ICU stay. Third, insufficient information of the causative disease may lead to bias in multivariate analysis. Fourth, we did not know the patient's serum iron levels or whether erythropoietin use may have affected RDW values. Finally, the follow-up length of mortality varied. We only use hospital mortality and 30-day all-cause mortality, and this may affect the assessment of prognosis.
Conclusions
We found that RDW appeared to be an independent prognostic marker in critically ill patients with AKI and higher RDW was associated with increased risk of mortality in these patients. However, our findings need to be confirmed by large prospective studies with longer follow-up.
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